vs
Side-by-side financial comparison of SOLAREDGE TECHNOLOGIES, INC. (SEDG) and Bio-Techne (TECH). Click either name above to swap in a different company.
SOLAREDGE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($335.4M vs $311.4M, roughly 1.1× Bio-Techne). Bio-Techne runs the higher net margin — 16.4% vs -39.4%, a 55.8% gap on every dollar of revenue. On growth, SOLAREDGE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (70.9% vs -1.5%). Over the past eight quarters, SOLAREDGE TECHNOLOGIES, INC.'s revenue compounded faster (28.1% CAGR vs 1.3%).
SolarEdge Technologies, Inc. is an Israeli company that developed a DC optimized inverter system.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
SEDG vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $335.4M | $311.4M |
| Net Profit | $-132.1M | $51.0M |
| Gross Margin | 22.2% | 66.9% |
| Operating Margin | -14.4% | 24.2% |
| Net Margin | -39.4% | 16.4% |
| Revenue YoY | 70.9% | -1.5% |
| Net Profit YoY | 54.0% | 126.0% |
| EPS (diluted) | $-2.21 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $311.4M | ||
| Q4 25 | $335.4M | $295.9M | ||
| Q3 25 | $340.2M | — | ||
| Q2 25 | $289.4M | $317.0M | ||
| Q1 25 | $219.5M | $316.2M | ||
| Q4 24 | $196.2M | $297.0M | ||
| Q3 24 | $235.4M | $289.5M | ||
| Q2 24 | $265.4M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | $-132.1M | $38.0M | ||
| Q3 25 | $-50.1M | — | ||
| Q2 25 | $-124.7M | $-17.7M | ||
| Q1 25 | $-98.5M | $22.6M | ||
| Q4 24 | $-287.4M | $34.9M | ||
| Q3 24 | $-1.2B | $33.6M | ||
| Q2 24 | $-130.8M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | 22.2% | 64.6% | ||
| Q3 25 | 21.2% | — | ||
| Q2 25 | 11.1% | 62.7% | ||
| Q1 25 | 8.0% | 67.9% | ||
| Q4 24 | -57.2% | 65.3% | ||
| Q3 24 | -309.1% | 63.2% | ||
| Q2 24 | -4.1% | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | -14.4% | 18.4% | ||
| Q3 25 | -10.3% | — | ||
| Q2 25 | -39.9% | -7.5% | ||
| Q1 25 | -46.8% | 12.2% | ||
| Q4 24 | -134.4% | 16.0% | ||
| Q3 24 | -471.8% | 13.8% | ||
| Q2 24 | -60.4% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | -39.4% | 12.8% | ||
| Q3 25 | -14.7% | — | ||
| Q2 25 | -43.1% | -5.6% | ||
| Q1 25 | -44.9% | 7.1% | ||
| Q4 24 | -146.5% | 11.7% | ||
| Q3 24 | -522.8% | 11.6% | ||
| Q2 24 | -49.3% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $-2.21 | $0.24 | ||
| Q3 25 | $-0.84 | — | ||
| Q2 25 | $-2.13 | $-0.11 | ||
| Q1 25 | $-1.70 | $0.14 | ||
| Q4 24 | $-5.00 | $0.22 | ||
| Q3 24 | $-21.58 | $0.21 | ||
| Q2 24 | $-2.31 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $493.2M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $427.5M | $2.1B |
| Total Assets | $2.2B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | $493.2M | $172.9M | ||
| Q3 25 | $498.6M | — | ||
| Q2 25 | $758.0M | $162.2M | ||
| Q1 25 | $651.6M | $140.7M | ||
| Q4 24 | $585.9M | $177.5M | ||
| Q3 24 | $678.8M | $187.5M | ||
| Q2 24 | $689.8M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $427.5M | $2.0B | ||
| Q3 25 | $479.8M | — | ||
| Q2 25 | $513.2M | $1.9B | ||
| Q1 25 | $594.2M | $2.0B | ||
| Q4 24 | $658.3M | $2.1B | ||
| Q3 24 | $930.9M | $2.1B | ||
| Q2 24 | $2.1B | $2.1B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $2.2B | $2.5B | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.5B | $2.6B | ||
| Q1 25 | $2.5B | $2.6B | ||
| Q4 24 | $2.6B | $2.7B | ||
| Q3 24 | $2.8B | $2.7B | ||
| Q2 24 | $3.9B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $52.6M | — |
| Free Cash FlowOCF − Capex | $43.3M | — |
| FCF MarginFCF / Revenue | 12.9% | — |
| Capex IntensityCapex / Revenue | 2.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $80.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $52.6M | — | ||
| Q3 25 | $25.6M | — | ||
| Q2 25 | $-7.8M | $98.2M | ||
| Q1 25 | $33.8M | $41.1M | ||
| Q4 24 | $37.8M | $84.3M | ||
| Q3 24 | $-89.3M | $63.9M | ||
| Q2 24 | $-44.8M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | $43.3M | — | ||
| Q3 25 | $22.8M | — | ||
| Q2 25 | $-9.1M | $93.3M | ||
| Q1 25 | $23.7M | $31.0M | ||
| Q4 24 | $25.5M | $77.5M | ||
| Q3 24 | $-136.7M | $54.7M | ||
| Q2 24 | $-67.0M | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | 12.9% | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | -3.1% | 29.4% | ||
| Q1 25 | 10.8% | 9.8% | ||
| Q4 24 | 13.0% | 26.1% | ||
| Q3 24 | -58.1% | 18.9% | ||
| Q2 24 | -25.2% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.4% | 1.5% | ||
| Q1 25 | 4.6% | 3.2% | ||
| Q4 24 | 6.2% | 2.3% | ||
| Q3 24 | 20.1% | 3.2% | ||
| Q2 24 | 8.4% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SEDG
| Other | $197.7M | 59% |
| Europe Except Netherlands | $99.4M | 30% |
| Others | $38.2M | 11% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
